Table 4 |
|||
| PFS (progression free survival) according to KRAS mutation for the two different treatment arms | |||
| PFS | FUFOX | CAPOX | p-value (log rank) |
| n = 105 | n = 96 | HR (95% CI) | |
| All patients | 8.2 months | 6.4 months |
0.18 0.81 (0.61-1.09) |
| WT | 8.1months | 6.4months | 0.29 |
| 0.82 (0.56-1.19) | |||
| Codon 12 mutation | 9.9months | 7.0months | 0.12 |
| 0.62 (0.33-1.14) | |||
| Codon 13 mutation | 6.1months | 13.3months | 0.22 |
| 2.52 (0.54-11.70) | |||
PFS, HR hazard ratio by cox regression, CI confidence interval, WT wild type.
Reinacher-Schick et al. BMC Cancer 2012 12:349 doi:10.1186/1471-2407-12-349
